IL-15

Combined IL-15/IL-15R Immunotherapy Maximizes IL-15 Activity In Vivo

Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15

Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...

IL-15-high-responder developing NK cells bearing Ly49 receptors in IL-15-/- mice.

In mice lacking IL-15, NK cell development is arrested at immature stages, providing an opportunity to investigate the earliest developing NK cells that would respond to IL-15. We show in this study that immature NK cells were present in the spleen as well as bone marrow (BM) and contained IL-15-high-responder cells. Thus, mature NK cells were generated more efficiently from IL-15(-/-) than fro...

Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils.

Interleukin-2 (IL-2) and IL-15 exert similar biological actions, which largely reflect the fact that their receptors share common beta and gamma subunits; in contrast, distinct subunits are required for high-affinity binding of either cytokine to a heterotrimeric receptor complex. Human neutrophils are known to express both the beta and gamma subunits of the IL-2/IL-15 receptor complex, and we ...

Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus

Myxoma virus, a rabbit poxvirus, can efficiently infect various classes of mouse and human cancer cells. It is a strict rabbit-specific pathogen, safe to use in all non-rabbit hosts tested including mice and humans. Recombinant viruses were previously engineered to express tdTomatoRed fluorescent protein (vMyx-tdTr) and mouse interleukin-15 (vMyx-IL15-tdTr). IL15 is an immunomodulatory cytokine...